GlassScriptPhysician profile
Paul A Hinton
NPI 1639130263
$8,554.43
in general payments reported to CMS, 2019-2025
59 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,233 · 2020: $1,283 · 2021: $1,714 · 2022: $1,511 · 2023: $1,198 · 2024: $1,234 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Debt Forgiveness: $14.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.89 |
| Debt Forgiveness | $14.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,149.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,109.92 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $683.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $585.24 | 2020-2024 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $518.19 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Novartis Pharmaceuticals Corporation | $456.08 | 2021-2025 | |
| Pfizer INC. | $366.19 | 2019-2025 | |
| Novo Nordisk INC | $353.50 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $332.59 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Supernus Pharmaceuticals, INC. | $321.10 | 2019-2024 | Qelbree |
| Amarin Pharma, INC. | $216.83 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.22 | 2019-2024 | Jardiance |
| Ironshore Pharmaceuticals INC. | $147.18 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.59 | 2021-2025 | Caplyta |
| Mylan Specialty L.P. | $119.71 | 2022-2024 | Yupelri |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.